Cell Growth & Differentiation, Vol 6, Issue 7 863-869, Copyright © 1995 by American Association of Cancer Research

ARTICLES

Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide

R Pellegrini, A Mariotti, E Tagliabue, R Bressan, G Bunone, D Coradini, G Della Valle, F Formelli, L Cleris and P Radice
Dipartimento di Oncologia Sperimentale, Istituto Nazionale Tumori, Milano, Italy.

The retinoid N-(hydroxyphenyl) retinamide (4-HPR) appears to be a promising tool for chemoprevention of breast carcinoma, and clinical trials to evaluate its effect are in progress. However, its action on tumor cells has remained largely undefined. We report here that 4-HPR induced apoptosis and/or differentiation in breast cancer cell lines, independent of hormone receptor status and retinoic acid receptor expression, although it was slightly more efficient in inhibiting proliferation of estrogen receptor-positive cells. 4-HPR up-modulated expression of several differentiation markers (class 1 HLA, laminin, and beta 1 integrin chain) and down-regulated expression of molecules associated with tumor progression, including the p185/HER2 oncoprotein, the epidermal growth factor receptor, and the M(r) 67,000 laminin receptor. These data suggest that 4-HPR could exert a beneficial effect by inhibiting cell proliferation and modulating breast tumor aggressiveness.

This article has been cited by other articles:

				A. L. Anding, J. S. Chapman, D. W. Barnett, R. W. Curley Jr., and M. Clagett-Dame The Unhydrolyzable Fenretinide Analogue 4-Hydroxybenzylretinone Induces the Proapoptotic Genes GADD153 (CHOP) and Bcl-2-Binding Component 3 (PUMA) and Apoptosis that Is Caspase- Dependent and Independent of the Retinoic Acid Receptor Cancer Res., July 1, 2007; 67(13): 6270 - 6277. [Abstract] [Full Text] [PDF]

				J. G. Villablanca, M. D. Krailo, M. M. Ames, J. M. Reid, G. H. Reaman, and C. P. Reynolds Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709) J. Clin. Oncol., July 20, 2006; 24(21): 3423 - 3430. [Abstract] [Full Text] [PDF]

				U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Ann. Onc., July 1, 2006; 17(7): 1065 - 1071. [Abstract] [Full Text] [PDF]

				K. I. Pritchard Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact? Ann. Onc., July 1, 2006; 17(7): 1035 - 1036. [Full Text] [PDF]

				K. J. Soprano and D. R. Soprano Retinoic Acid Receptors and Cancer J. Nutr., December 1, 2002; 132(12): 3809S - 3813. [Abstract] [Full Text] [PDF]

				G. C. Rodriguez, N. P. Nagarsheth, K. L. Lee, R. C. Bentley, D. K. Walmer, M. Cline, R. S. Whitaker, P. Isner, A. Berchuck, R. K. Dodge, et al. Progestin-Induced Apoptosis in the Macaque Ovarian Epithelium: Differential Regulation of Transforming Growth Factor-{beta} J Natl Cancer Inst, January 2, 2002; 94(1): 50 - 60. [Abstract] [Full Text] [PDF]

				S. Guruswamy, S. Lightfoot, M. A. Gold, R. Hassan, K. D. Berlin, R. T. Ivey, and D. M. Benbrook Effects of Retinoids on Cancerous Phenotype and Apoptosis in Organotypic Cultures of Ovarian Carcinoma J Natl Cancer Inst, April 4, 2001; 93(7): 516 - 525. [Abstract] [Full Text] [PDF]

				S. Menard, T. Camerini, L. Mariani, G. Tomasic, S. Pilotti, A. Costa, G. De Palo, and U. Veronesi Re: Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer J Natl Cancer Inst, February 7, 2001; 93(3): 240 - 241. [Full Text] [PDF]

				S. M. Schneider, M. Offterdinger, H. Huber, and T. W. Grunt Activation of Retinoic Acid Receptor {{alpha}} Is Sufficient for Full Induction of Retinoid Responses in SK-BR-3 and T47D Human Breast Cancer Cells Cancer Res., October 1, 2000; 60(19): 5479 - 5487. [Abstract] [Full Text]

				U. Veronesi, G. De Palo, E. Marubini, A. Costa, F. Formelli, L. Mariani, A. Decensi, T. Camerini, M. R. Del Turco, M. G. Di Mauro, et al. Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1847 - 1856. [Abstract] [Full Text] [PDF]

				M. Campiglio, Y. Pekarsky, S. Menard, E. Tagliabue, S. Pilotti, and C. M. Croce FHIT Loss of Function in Human Primary Breast Cancer Correlates with Advanced Stage of the Disease Cancer Res., August 1, 1999; 59(16): 3866 - 3869. [Abstract] [Full Text] [PDF]

				R. K. Srivastava, A. R. Srivastava, Y. S. Cho-Chung, and D. L. Longo Synergistic Effects of Retinoic Acid and 8-Chloro-Adenosine 3',5'-Cyclic Monophosphate on the Regulation of Retinoic Acid Receptor {beta} and Apoptosis: Involvement of Mitochondria Clin. Cancer Res., July 1, 1999; 5(7): 1892 - 1904. [Abstract] [Full Text] [PDF]

				G. C. Rodriguez, D. K. Walmer, M. Cline, H. Krigman, B. A. Lessey, R. S. Whitaker, R. Dodge, and C. L. Hughes Effect of Progestin on the Ovarian Epithelium of Macaques: Cancer Prevention Through Apoptosis? Reproductive Sciences, September 1, 1998; 5(5): 271 - 276. [Abstract] [PDF]

				A. N. Fanjul, D. Delia, M. A. Pierotti, D. Rideout, J. Qiu, and M. Pfahl 4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid Receptors J. Biol. Chem., September 13, 1996; 271(37): 22441 - 22446. [Abstract] [Full Text] [PDF]